BioMarin’s Voxzogo obtains Japan’s MHLW approval for achondroplasia
In a Phase III trial, treatment with Voxzogo offered transient declines in blood pressure.

In a Phase III trial, treatment with Voxzogo offered transient declines in blood pressure.
Despite developments, epigenetic clocks and similar longevity technologies remain expensive.
ByThe vaccine obtained authorisation from the Ministry of Health, Labour and Welfare of Japan to prevent Covid-19.
In addition to an approved drug and vaccine, US agencies are negotiating the procurement of a second antiviral to bolster…
ByAnGes will make upfront and milestone payments up to $1.5m to Eiger, under the deal.
The authorisation is based on the positive interim findings from the Phase II/III KidCOVE clinical trial of the vaccine.
On March 31, 2022, Outlook Therapeutics submitted a Biologics License Application (BLA) to the FDA for ONS-5010 (bevacizumab-vikg) for the…
ByTakeda will manufacture the vaccines at its Hikari facility in Japan for supply in the country.
Thank you for subscribing to Pharmaceutical Technology